Vir's pivotal Phase 3 ECLIPSE 1 trial of elebsiran and tobevibart in chronic hepatitis delta met its primary endpoint: 44% of patients hit undetectable virus plus normal ALT at Week 48 (vs 0% in the delayed-treatment group), and 79% had undetectable virus. The Phase 2 SOLSTICE data was equally strong, with all 28 patients completing 96 weeks undetectable. Vir plans a U.S. FDA filing in mid-2027, with the two remaining pivotal trials reading out in early 2027.
Useful?